Lachlan Campbell-Verduyn is an associate in the firm's Litigation department. She has represented biotech and pharmaceutical companies in patent litigation on a variety of subject matters ranging from small molecules to biologics. She has experience litigating cases brought under the Hatch-Waxman act, and is representing an innovator pharmaceutical company in one of the first cases under the U.S. biosimilars legislation (the BPCIA).
Ms. Campbell-Verduyn has a Ph.D. in Organic Chemistry from Rijksuniversiteit Groningen, in the Netherlands, where she developed new radiolabelled tracers for disease imaging, and an undergraduate degree in Chemistry from Mount Allison University, in Canada.
Representing innovator company in one of the first cases under the legislation for biosimilars (BPCIA) and the first involving an antibody product.
Performed pre-suit investigation for potential Paragraph IV challenges to blockbuster drug.
Represented educational institution in trademark opposition and cancellation proceedings before U.S. Patent & Trademark Office. Obtained favorable outcome for client in both proceedings.
Representing an individual client with their application to the Executive Clemency Bureau of the New York State Department of Corrections and Community Supervision under the auspices of the New York State’s Pro Bono Clemency Program.
- U.S. Court of Appeals, Federal Circuit
- U.S. District Court, Southern and Eastern Districts of New York
- New York
- Contributor to BiologicsBlog.com
- Co-Authored Supreme Court Amicus Brief for the New York Intellectual Property Law Association regarding Daiichi Sankyo Company, Ltd. v. Michelle K. Lee, Director, U.S. Patent and Trademark Office, No. 15-652 (December 16, 2015)